MCID: KHN001
MIFTS: 48

Kuhnt-Junius Degeneration

Categories: Eye diseases

Aliases & Classifications for Kuhnt-Junius Degeneration

MalaCards integrated aliases for Kuhnt-Junius Degeneration:

Name: Kuhnt-Junius Degeneration 12 15
Neovascular Age-Related Macular Degeneration 12 15
Exudative Senile Macular Degeneration of Retina 12
Exudative Age-Related Macular Degeneration 71
Wet Senile Macular Retinal Degeneration 12
Senile Macular Degeneration, Wet 12
Exudative Macular Degeneration 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10873
ICD9CM 34 362.52
SNOMED-CT 67 11290001 16018000
ICD10 32 H35.32
UMLS 71 C0271084 C2237660

Summaries for Kuhnt-Junius Degeneration

MalaCards based summary : Kuhnt-Junius Degeneration, also known as neovascular age-related macular degeneration, is related to central serous chorioretinopathy and endophthalmitis. An important gene associated with Kuhnt-Junius Degeneration is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Verteporfin and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Kuhnt-Junius Degeneration

Diseases related to Kuhnt-Junius Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 central serous chorioretinopathy 31.3 CFH ARMS2
2 endophthalmitis 31.3 VEGFB VEGFA PLG PGF FLT1
3 vitreous detachment 31.2 VEGFB VEGFA PLG FAM187A
4 retinal detachment 31.1 VEGFA SERPINF1 COL18A1
5 angioid streaks 30.9 VEGFA CFHR2 CFH ARMS2
6 severe nonproliferative diabetic retinopathy 30.8 VEGFA PGF
7 retinal vein occlusion 30.7 VEGFA SERPINF1 KDR
8 microvascular complications of diabetes 1 30.7 VEGFA SERPINF1 FLT1
9 macular holes 30.6 VEGFA SERPINF1 PLG FAM187A
10 macular degeneration, age-related, 6 30.5 CFH CFB
11 keratitis, hereditary 30.5 VEGFC VEGFA FLT1
12 leukostasis 30.4 VEGFA SERPINF1 KDR CFHR2
13 eales disease 30.4 VEGFA SERPINF1
14 macular retinal edema 30.4 VEGFB VEGFA SERPINF1 PLG PGF KDR
15 central retinal vein occlusion 30.3 VEGFA SERPINF1 PLG
16 microvascular complications of diabetes 5 30.1 VEGFA TEK SERPINF1 PLG PGF KDR
17 choroiditis 30.0 VEGFA HTRA1 CFH CFB ARMS2
18 diabetic macular edema 29.1 VEGFC VEGFB VEGFA TEK SERPINF1 PGF
19 retinal vascular disease 29.0 VEGFB VEGFA TEK SERPINF1 PLG PGF
20 neovascular glaucoma 29.0 VEGFD VEGFC VEGFB VEGFA PLG PGF
21 eye disease 28.9 VEGFA SERPINF1 PLG PGF KDR HTRA1
22 exudative vitreoretinopathy 1 26.8 VLDLR VEGFC VEGFB VEGFA TEK SERPINF1
23 macular degeneration, age-related, 1 24.9 VLDLR VEGFD VEGFC VEGFB VEGFA TEK
24 yemenite deaf-blind hypopigmentation syndrome 11.1
25 periodontal ehlers-danlos syndrome 10.8
26 hydrops, lactic acidosis, and sideroblastic anemia 10.7
27 cataract 10.7
28 triiodothyronine receptor auxiliary protein 10.6
29 macular degeneration, age-related, 12 10.6
30 uveitis 10.6
31 retinal disease 10.6
32 48,xyyy 10.6
33 thrombotic microangiopathy 10.5 VEGFA CFH
34 scotoma 10.5
35 47,xyy 10.5
36 ocular hypertension 10.5
37 cytokine deficiency 10.5
38 septate uterus 10.5 KDR FLT1
39 atypical hemolytic uremic syndrome with complement gene abnormality 10.5 CFH CFB
40 hypercholesterolemia, familial, 1 10.4
41 myopia 10.4
42 vascular disease 10.4
43 optic nerve disease 10.4
44 charles bonnet syndrome 10.4
45 angiokeratoma of mibelli 10.4 KDR FLT1
46 radiation proctitis 10.4 VEGFA KDR
47 genetic atypical hemolytic-uremic syndrome 10.4 CFH CFB
48 bullous retinoschisis 10.4 VEGFA CFH ARMS2
49 c3 glomerulopathy 10.4 CFH CFB
50 lipodermatosclerosis 10.4 VEGFA FLT1

Graphical network of the top 20 diseases related to Kuhnt-Junius Degeneration:



Diseases related to Kuhnt-Junius Degeneration

Symptoms & Phenotypes for Kuhnt-Junius Degeneration

MGI Mouse Phenotypes related to Kuhnt-Junius Degeneration:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 CFB CFH COL18A1 FLT1 HTRA1 KDR
2 growth/size/body region MP:0005378 10.18 CFH FLT1 HTRA1 KDR PDGFC PGF
3 homeostasis/metabolism MP:0005376 10.17 CFB CFH COL18A1 FLT1 KDR PDGFC
4 nervous system MP:0003631 10.03 CFH COL18A1 FLT1 KDR PDGFC PLG
5 normal MP:0002873 9.76 CFB CFH FLT1 KDR PDGFC TEK
6 vision/eye MP:0005391 9.44 CFH COL18A1 FLT1 HTRA1 KDR PDGFC
7 pigmentation MP:0001186 9.35 CFH COL18A1 PDGFC SERPINF1 VLDLR

Drugs & Therapeutics for Kuhnt-Junius Degeneration

Drugs for Kuhnt-Junius Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verteporfin Approved, Investigational Phase 4 129497-78-5
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
4
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
5
Bevacizumab Approved, Investigational Phase 4 216974-75-3
6
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
7 Dermatologic Agents Phase 4
8 Photosensitizing Agents Phase 4
9 Omega 3 Fatty Acid Phase 4
10 Cyclooxygenase Inhibitors Phase 4
11 Ketorolac Tromethamine Phase 4
12 Tocolytic Agents Phase 4
13 Pyranoprofen Phase 4
14 Autoantibodies Phase 4
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Antirheumatic Agents Phase 4
18 Analgesics Phase 4
19 Gastrointestinal Agents Phase 4
20 Cathartics Phase 4
21 Laxatives Phase 4
22 Carboxymethylcellulose Sodium Phase 4
23 Pharmaceutical Solutions Phase 4
24 Antineoplastic Agents, Immunological Phase 4
25
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
26
Dorzolamide Approved Phase 2, Phase 3 120279-96-1 3154 5284549
27
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
28
Iodine Approved, Investigational Phase 3 7553-56-2 807
29
Povidone Approved Phase 3 9003-39-8
30
Povidone-iodine Approved Phase 3 25655-41-8
31
tannic acid Approved Phase 3 1401-55-4
32
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
33
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
34
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
35
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
36 Anecortave Investigational Phase 3 10184-70-0
37 Immunologic Factors Phase 3
38 triamcinolone acetonide Phase 3
39 Hormone Antagonists Phase 3
40 Triamcinolone diacetate Phase 3
41 Immunosuppressive Agents Phase 3
42 glucocorticoids Phase 3
43 Anti-Inflammatory Agents Phase 3
44 Hormones Phase 3
45 Triamcinolone hexacetonide Phase 3
46 Antihypertensive Agents Phase 2, Phase 3
47 Anti-Arrhythmia Agents Phase 2, Phase 3
48 Carbonic Anhydrase Inhibitors Phase 2, Phase 3
49 Fibrinolytic Agents Phase 2, Phase 3
50 Antibiotics, Antitubercular Phase 3

Interventional clinical trials:

(show top 50) (show all 375)
# Name Status NCT ID Phase Drugs
1 Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations Unknown status NCT01213667 Phase 4 Ranibizumab
2 Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
3 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
4 Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) Unknown status NCT01961414 Phase 4 Aflibercept
5 A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD). Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
6 Efficacy of Ranibizumab (Lucentis) in Combination With Photodynamic Therapy for Neovascular Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
7 A Multicenter Study Comparing Efficacy and Safety of " Treat-and-Extend" Regimen Versus PRN Regimen of Conbercept in Neovascular Age-related Macular Degeneration Unknown status NCT02802657 Phase 4 Conbercept
8 A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
9 A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study) Completed NCT01617148 Phase 4 Aflibercept
10 LUCAS. A Randomized, Prospective, Multicenter Study Comparing the Effect of Intravitreal Injection of Bevacizumab to Ranibizumab When Given to Patients With Neovascular Age-related Macular Degeneration Completed NCT01127360 Phase 4 Bevacizumab;Ranibizumab
11 Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
12 Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration. Completed NCT02321839 Phase 4 Intraviteal Ranibizumab 0.5mg
13 Size Progression of Non-Exudative Age-Related Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
14 A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients Completed NCT01988662 Phase 4
15 Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration Completed NCT02125864 Phase 4 Aflibercept
16 FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration Completed NCT01500915 Phase 4 Ranibizumab
17 Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy. Completed NCT01896284 Phase 4 0.5mg aflibercept
18 A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular Age Related Macular Degeneration (AMD) Completed NCT01775124 Phase 4 Ranibizumab
19 A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration Completed NCT02060604 Phase 4 Ketorolac + Ranibizumab;Ranibizumab
20 Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Exudative Age-Related Macular Degeneration Completed NCT03261635 Phase 4 Ranibizumab Injection;Indomethacin
21 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
22 Clinical Research of Photodynamic Therapy for Exudative Age-related Macular Degeneration Accompanied With Polypoidal Choroidal Vasculopathy Completed NCT00331435 Phase 4
23 A Prospective, Interventional Case Series, Effect of Lucentis on Indocyanine Angiographic Changes in Patients With Wet Age-related Macular Degeneration Completed NCT01810042 Phase 4 ranibizumab
24 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
25 Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES) Completed NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
26 A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration Completed NCT02142296 Phase 4 Eylea
27 Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
28 Single or Combined Protocols for the Treatment of Patients With Neovascular Age-related Macular Degeneration: Compliance, Risk/Benefit and Cost/Benefit Ratios Completed NCT03552770 Phase 4 Bevacizumab
29 Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD Completed NCT02246829 Phase 4
30 A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Completed NCT01958918 Phase 4 Ranibizumab;Aflibercept
31 A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
32 A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration Completed NCT02257632 Phase 4 Ranibizumab 0.5 mg;Aflibercept 2 mg
33 A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg. Completed NCT02161575 Phase 4 Ranibizumab
34 A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study). Completed NCT01863199 Phase 4 Lucentis (Treat and extend);Lucentis every 4 weeks;Lucentis every 12 weeks
35 Efficacy of Fixed Monthly Dosing of Lucentis® (Ranibizumab) on Subretinal Fluid (SRF) Associated With Persistent Pigment Epithelial Detachment (PED) in Neovascular Age-related Macular Degeneration (AMD): A Pilot Study Completed NCT02944227 Phase 4 Lucentis
36 An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD Completed NCT02577107 Phase 4 ranibizumab;Conbercept
37 Clinical and Genetic Assessment of Treatment Response in Patients With Age-related Macular Degeneration Using Intravitreal Aflibercept Injection Completed NCT02689518 Phase 4 Intravitreal aflibercept injection
38 VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis Completed NCT01464723 Phase 4 Ranibizumab
39 AflibercepT for Subjects Who Are Incomplete Responders to mUltiple Intravitreal Injections of Ranibizumab, Anti-VegF (The TURF Study) Completed NCT01543568 Phase 4 aflibercept 2.0 mg
40 A Prospective Pilot Study of Reduced Fluence Photodynamic Therapy With Visudyne® (Verteporfin) in Combination With Lucentis™ (Ranibizumab) for the Treatment of Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
41 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
42 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
43 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
44 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
45 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Aflibercept Treatment: The COVARIANT Study Recruiting NCT03056079 Phase 4 Intravitreal aflibercept
46 The IAI-OCTA Study or; Microvascular Structure and Morphology of Neovascular Membranes in Age Related Macular Degeneration (AMD) After Intravitreal Aflibercept Injection (IAI) Therapy Using OCT-Angiography Analysis Recruiting NCT03022292 Phase 4 Aflibercept Ophthalmic
47 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Ranibizumab Treatment: The COVERT Study Recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
48 Intraocular Cytokine Changes in Recurrence of Polypoidal Choroidal Vasculopathy Active, not recruiting NCT02976194 Phase 4 ranibizumab
49 Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial Enrolling by invitation NCT03918590 Phase 4 nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI)
50 OCTA-Directed PDT Triple Therapy for Treatment-Naïve Patients With Exudative Age-Related Macular Degeneration Versus Standard of Care Anti-VEGF(Anti-vascular Endothelial Growth Factor) Monotherapy Not yet recruiting NCT04075136 Phase 4 Ranibizumab;Triamcinolone Acetonide;verteporfin

Search NIH Clinical Center for Kuhnt-Junius Degeneration

Genetic Tests for Kuhnt-Junius Degeneration

Anatomical Context for Kuhnt-Junius Degeneration

MalaCards organs/tissues related to Kuhnt-Junius Degeneration:

40
Eye, Endothelial, Retina, Testes, Bone, Bone Marrow, Monocytes

Publications for Kuhnt-Junius Degeneration

Articles related to Kuhnt-Junius Degeneration:

(show top 50) (show all 2666)
# Title Authors PMID Year
1
SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States. 61
31812631 2020
2
CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus. 61
32032258 2020
3
Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. 61
31540854 2020
4
Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). 61
31619357 2020
5
MACULAR ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Post Hoc Analysis of Patients With Pigment Epithelial Detachments. 61
31972796 2020
6
Hyperreflective foci in predicting the treatment outcome of antivascular endothelial growth factor in neovascular age-related macular degeneration. 61
31828425 2020
7
Investigation of circRNA Expression Profiles and Analysis of circRNA-miRNA-mRNA Networks in an Animal (Mouse) Model of Age-Related Macular Degeneration. 61
31979995 2020
8
Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. 61
32020843 2020
9
Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. 61
31791663 2020
10
Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. 61
32019921 2020
11
A telomerase-derived peptide vaccine inhibits laser-induced choroidal neovascularization in a rat model. 61
31655029 2020
12
Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. 61
31647931 2020
13
Effect of Inhibition of Colony-Stimulating Factor 1 Receptor on Choroidal Neovascularization in Mice. 61
31783006 2020
14
Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. 61
31606444 2020
15
H2 O2 induces oxidative stress damage through the BMP-6/SMAD/hepcidin axis. 61
32012242 2020
16
Sociodemographic Factors in Neovascular Age-Related Macular Degeneration. 61
31785890 2020
17
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial. 61
32027349 2020
18
Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? 61
31735634 2020
19
New therapeutic targets in the treatment of age-related macular degeneration. 61
31787390 2020
20
Association Between Visit Adherence and Visual Acuity in Neovascular Age-Related Macular Degeneration. 61
32027366 2020
21
Comparison of two different treatment regimens' efficacy in neovascular age-related macular degeneration in Turkish population-based on real life data-Bosphorus RWE Study Group. 61
31956577 2020
22
Long-term Clinical Course after Vitrectomy for Breakthrough Vitreous Hemorrhage Secondary to Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. 61
31941971 2020
23
EN FACE VERSUS 12-LINE RADIAL OPTICAL COHERENCE TOMOGRAPHY SCAN PATTERNS FOR DETECTION OF MACULAR FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 61
28816861 2020
24
Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. 61
31743912 2020
25
Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study. 61
31918685 2020
26
A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. 61
31918701 2020
27
Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19. 61
31395505 2020
28
Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes. 61
31324588 2020
29
Assessment of reporting quality of meta-analyses of randomized controlled trials in neovascular age-related macular degeneration published from April 2014 to May 2018 using prisma statement. 61
31912405 2020
30
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. 61
31900438 2020
31
Intravitreal Recombinant Tissue Plasminogen Activator and Sulphur Hexafluoride gas for Submacular Hemorrhage Displacement in Age-Related Macular Degeneration: Looking Behind the Blood. 61
31905361 2020
32
A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II. 61
31907843 2020
33
CLINICAL CHARACTERISTICS OF THE CHARLES BONNET SYNDROME IN PATIENTS WITH NEOVASCULAR-AGE RELATED MACULAR DEGENERATION: THE IMPORTANCE OF EARLY DETECTION. 61
31986513 2020
34
Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients. 61
31914968 2020
35
PREDICTORS OF RECURRENT EXUDATION IN CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION DURING A TREATMENT-FREE PERIOD. 61
31922495 2020
36
Impact of optical coherence tomography angiography on the non-invasive diagnosis of neovascular age-related macular degeneration. 61
31900638 2020
37
Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study. 61
31079057 2020
38
Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. 61
31302628 2020
39
Ophthalmology Retina Enters Year 4: Some Comments on Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. 61
31902470 2020
40
The Value of Prior Response to Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration: A HARBOR Subanalysis. 61
31416763 2020
41
An association of neovascular age-related macular degeneration with polymorphisms of CFH, ARMS2, HTRA1 and C3 genes in Czech population. 61
31970928 2020
42
Comment on: Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. 61
31699292 2020
43
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. 61
30986442 2020
44
Author Correction: Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment. 61
31949251 2020
45
Anatomical and functional changes in neovascular AMD in remission: comparison of fibrocellular and fibrovascular phenotypes. 61
31000509 2020
46
Comparison of OCT and OCTA manifestations among untreated PCV, neovascular AMD, and CSC in Chinese population. 61
31956576 2020
47
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial. 61
31917441 2020
48
Effects of three intravitreal injections of aflibercept on the ocular circulation in eyes with age-related maculopathy. 61
30979731 2020
49
Utility of a public-available artificial intelligence in diagnosis of polypoidal choroidal vasculopathy. 61
31686211 2020
50
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. 61
32001821 2020

Variations for Kuhnt-Junius Degeneration

Expression for Kuhnt-Junius Degeneration

Search GEO for disease gene expression data for Kuhnt-Junius Degeneration.

Pathways for Kuhnt-Junius Degeneration

Pathways related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 VEGFD VEGFC VEGFB SERPINF1 PLG PGF
2
Show member pathways
13.81 VEGFD VEGFC VEGFB VEGFA TEK PGF
3
Show member pathways
13.69 VEGFD VEGFC VEGFB VEGFA TEK PGF
4
Show member pathways
13.52 VEGFD VEGFC VEGFB TEK PGF PDGFC
5
Show member pathways
13.52 VEGFD VEGFC VEGFB VEGFA TEK PGF
6
Show member pathways
13.4 VEGFD VEGFC VEGFB TEK PGF PDGFC
7
Show member pathways
13.31 VEGFD VEGFC VEGFB TEK PGF PDGFC
8
Show member pathways
13.28 VEGFD VEGFC VEGFB TEK PGF PDGFC
9
Show member pathways
13.27 VEGFD VEGFC VEGFB VEGFA TEK PGF
10
Show member pathways
13.07 VEGFD VEGFC VEGFB PGF PDGFC KDR
11
Show member pathways
13.04 VEGFD VEGFC VEGFB PGF PDGFC KDR
12
Show member pathways
12.89 VEGFD VEGFC VEGFB VEGFA TEK PGF
13
Show member pathways
12.88 VEGFD VEGFC VEGFB VEGFA PGF PDGFC
14 12.79 VEGFD VEGFC VEGFB VEGFA PGF
15
Show member pathways
12.7 VEGFD VEGFC VEGFB PGF PDGFC KDR
16 12.48 VEGFD VEGFC VEGFB VEGFA TEK PGF
17
Show member pathways
12.4 VEGFD VEGFC VEGFB VEGFA KDR FLT1
18
Show member pathways
12.37 VEGFD VEGFC VEGFB VEGFA PGF KDR
19
Show member pathways
12.33 VEGFD VEGFC VEGFB TEK PGF PDGFC
20
Show member pathways
12.25 VEGFC VEGFB VEGFA KDR FLT1
21
Show member pathways
12.25 VEGFD VEGFC VEGFB PGF PDGFC KDR
22
Show member pathways
12.25 VEGFD VEGFC VEGFB VEGFA TEK PGF
23 12.15 VEGFC VEGFB TEK KDR FLT1
24 12.11 PLG CFHR2 CFH CFB
25
Show member pathways
11.92 VEGFA KDR FLT1
26 11.91 VEGFD VEGFC VEGFB VEGFA
27 11.9 VEGFA TEK FLT1
28 11.87 VEGFC VEGFB TEK KDR FLT1
29 11.83 PLG CFH CFB
30 11.82 VEGFA TEK FLT1
31 11.73 VEGFD VEGFC VEGFB PGF PDGFC
32
Show member pathways
11.7 VEGFC VEGFB VEGFA PGF KDR FLT1
33 11.62 VEGFD VEGFC VEGFB VEGFA
34 11.52 VEGFA PLG KDR
35 11.49 VEGFC VEGFB VEGFA
36 11.4 VEGFB VEGFA PDGFC KDR FLT1
37 11.34 VEGFA KDR FLT1
38 11.16 VEGFA TEK KDR FLT1
39 10.88 VEGFD VEGFC VEGFB TEK PGF PDGFC
40 10.69 VEGFC VEGFB VEGFA
41
Show member pathways
10.37 VEGFD VEGFC VEGFB VEGFA PGF KDR

GO Terms for Kuhnt-Junius Degeneration

Cellular components related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 VLDLR VEGFD VEGFC VEGFB VEGFA SERPINF1
2 receptor complex GO:0043235 9.56 VLDLR TEK KDR FLT1
3 platelet alpha granule lumen GO:0031093 9.55 VEGFD VEGFC VEGFB VEGFA PLG
4 extracellular region GO:0005576 9.53 VEGFD VEGFC VEGFB VEGFA TEK SERPINF1

Biological processes related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.19 VEGFD VEGFC VEGFA SHROOM3 PGF PDGFC
2 positive regulation of cell proliferation GO:0008284 10.13 VEGFD VEGFC VEGFA PGF PDGFC KDR
3 cell differentiation GO:0030154 10.12 VEGFD VEGFC VEGFA PGF KDR FLT1
4 positive regulation of protein phosphorylation GO:0001934 10.02 VEGFD VEGFC VEGFB VEGFA TEK PGF
5 positive regulation of angiogenesis GO:0045766 10.01 VEGFD VEGFC VEGFB VEGFA TEK PGF
6 response to hypoxia GO:0001666 9.99 VEGFD VEGFC VEGFB VEGFA TEK PGF
7 positive regulation of cell migration GO:0030335 9.97 VEGFA PDGFC KDR FLT1 COL18A1
8 angiogenesis GO:0001525 9.97 VEGFD VEGFC VEGFB VEGFA TEK PGF
9 response to drug GO:0042493 9.95 VEGFC VEGFB PGF COL18A1
10 platelet degranulation GO:0002576 9.93 VEGFD VEGFC VEGFB VEGFA PLG
11 positive regulation of cell division GO:0051781 9.93 VEGFD VEGFC VEGFB VEGFA PGF PDGFC
12 positive regulation of endothelial cell proliferation GO:0001938 9.91 VEGFD VEGFC VEGFB VEGFA TEK PGF
13 positive chemotaxis GO:0050918 9.89 VEGFD VEGFC VEGFB VEGFA PGF
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.85 TEK PDGFC KDR FLT1
15 regulation of complement activation GO:0030449 9.83 CFHR2 CFH CFB
16 induction of positive chemotaxis GO:0050930 9.83 VEGFD VEGFC VEGFB VEGFA PGF
17 positive regulation of epithelial cell proliferation GO:0050679 9.8 VEGFC VEGFA HTRA1
18 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.8 VEGFD VEGFC VEGFB VEGFA PGF KDR
19 positive regulation of MAP kinase activity GO:0043406 9.79 VEGFA PDGFC FLT1
20 positive regulation of endothelial cell migration GO:0010595 9.79 VEGFA TEK KDR
21 positive regulation of blood vessel endothelial cell migration GO:0043536 9.78 VEGFC VEGFA KDR
22 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.77 VEGFA KDR FLT1
23 positive regulation of focal adhesion assembly GO:0051894 9.74 VEGFA TEK KDR
24 positive regulation of protein autophosphorylation GO:0031954 9.73 VEGFC VEGFA PDGFC
25 complement activation, alternative pathway GO:0006957 9.64 CFH CFB
26 positive regulation of positive chemotaxis GO:0050927 9.63 VEGFA KDR
27 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.63 VEGFA PLG
28 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.6 VEGFA KDR
29 positive regulation of mast cell chemotaxis GO:0060754 9.55 VEGFD VEGFC VEGFB VEGFA PGF
30 vascular endothelial growth factor signaling pathway GO:0038084 9.5 VEGFD VEGFC VEGFB VEGFA PGF KDR
31 sprouting angiogenesis GO:0002040 9.23 VEGFD VEGFC VEGFB VEGFA TEK PGF

Molecular functions related to Kuhnt-Junius Degeneration according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.39 VLDLR VEGFD VEGFC VEGFB VEGFA TEK
2 protein homodimerization activity GO:0042803 10 VEGFD VEGFB VEGFA PGF PDGFC CFHR2
3 heparin binding GO:0008201 9.76 VEGFB VEGFA PGF CFH
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.65 TEK KDR FLT1
5 growth factor activity GO:0008083 9.63 VEGFD VEGFC VEGFB VEGFA PGF PDGFC
6 growth factor binding GO:0019838 9.56 TEK KDR HTRA1 FLT1
7 apolipoprotein binding GO:0034185 9.54 VLDLR PLG
8 vascular endothelial growth factor binding GO:0038085 9.51 KDR FLT1
9 platelet-derived growth factor receptor binding GO:0005161 9.5 VEGFD VEGFA PDGFC
10 vascular endothelial growth factor-activated receptor activity GO:0005021 9.49 KDR FLT1
11 vascular endothelial growth factor receptor 1 binding GO:0043183 9.4 VEGFB VEGFA
12 vascular endothelial growth factor receptor 3 binding GO:0043185 9.37 VEGFD VEGFC
13 chemoattractant activity GO:0042056 9.35 VEGFD VEGFC VEGFB VEGFA PGF
14 vascular endothelial growth factor receptor binding GO:0005172 9.02 VEGFD VEGFC VEGFB VEGFA PGF

Sources for Kuhnt-Junius Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....